Article

A real-world pharmacovigilance study of brentuximab vedotin based on the FAERS database from 2011 to 2024

2025-07-18

Abstract excerpt

<title>Abstract</title> <p>Brentuximab vedotin (BV) is an antibody-drug conjugate (ADC) that targets CD30 and is primarily used in the treatment of CD30-positive lymphoma. While BV has shown success in treating patients with this type of lymphoma, there have been reports of serious adverse drug events (ADEs) associated with its use. This study aims to investigate the ADEs related to BV reported in the FDA Adverse...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 97e05e7c-2afa-5603-ba14-e0b344b88838
DOI: 10.21203/rs.3.rs-6876929/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A real-world pharmacovigilance study of brentuximab vedotin based on the FAERS database from 2011 to 2024DOI 10.21203/rs.3.rs-6876929/v1Read

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Adverse events induced by Burosumab treatment and prediction of drug target gene: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS) databaseSemantic proximity Read

Adverse drug reactions associated with the use of biological agentsSemantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Real-world pharmacovigilance study of voclosporin based on FAERS and VigiBaseSemantic proximity Read

Immune-related adverse-event signals of durvalumab: cross-database pharmacovigilance analysis of WHO-VigiAccess and FAERS with comparative assessment versus atezolizumabSemantic proximity Read

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesSemantic proximity Read

Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports based on WHO Pharmacovigilance Database, VigiBaseSemantic proximity Read